Form 4: Summit Therapeutics Co-CEO Mahkam Zanganeh Buys Shares

Co-CEO Mahkam Zanganeh acquired 100,000 shares of Summit Therapeutics common stock at $14.60 per share.

Summary

• Co-CEO Mahkam Zanganeh purchased 100,000 shares of Summit Therapeutics (SMMT) common stock.
• The transaction occurred on June 4, 2026, at a price of $14.60 per share.
• Following the purchase, the reporting person maintains significant indirect beneficial ownership through various trusts and family holdings.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive signal, as significant open-market buying by a Co-CEO typically reflects strong internal confidence in the company's trajectory.

Positives

• Insider confidence is demonstrated by the Co-CEO's open-market purchase of 100,000 shares.
• The purchase signals management's alignment with shareholder interests and belief in the company's long-term value.

Negatives

• None identified in this filing.

Risks

• The reporting person disclaims beneficial ownership of a large portion of the reported securities, which may complicate the interpretation of total control or influence.

Future Outlook

The filing does not provide forward-looking guidance regarding company operations or financial performance.

Industry Context

StockSavvy.ai notes that insider buying in the biotechnology sector is often viewed as a positive indicator of management's confidence in upcoming clinical trial results or regulatory milestones.

Comparison to Industry Standards

• Insider purchases by high-level executives are generally considered a standard bullish signal in the pharmaceutical and biotech industries.
• The scale of the purchase is consistent with typical executive equity accumulation patterns.

Related Party Transactions

• The filing discloses holdings through the Mahkam Zanganeh Revocable Trust, the Shaun Zanganeh Irrevocable Trust, and holdings by a spouse and immediate family member.

Stakeholder Impact

• Shareholders may interpret this purchase as a vote of confidence in the company's current strategic direction.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Recommendation

While insider buying is a positive signal, it should be weighed against the company's broader clinical pipeline and financial fundamentals before making a buy decision.

Keywords

Summit Therapeutics, SMMT, Insider Trading, Form 4, Mahkam Zanganeh, Biotech